Skip to main content
. 2023 Jun 3;48(11):1648–1658. doi: 10.1038/s41386-023-01606-3

Table 1.

Descriptive and demographic data.

Variable Mean (∓SD) Ketamine Midazolam Statistics (df),p
Gender (M/F) 10/4 7/6 Χ2(1) = 0.16, p = n.s
Age 40.7 (∓10.7) 35.1 (∓10.34) t(24) = 1.35, p = n.s
Race/Ethnicity Black - 1 Black - 1 Χ2(5) = 3.04, p = n.s
Hispanic - 2 Hispanic - 0
American Indian - 0 American Indian - 1
Asian - 0 Asian - 1
Hawaiian - 1 Hawaiian - 0
White - 11 White - 10
Unknown - 1 Unknown -1
PCL-5 Before Treatment 48.8 (∓12.3) 44.4 (∓14.4) t(25) = 0.85, p = n.s
PCL-5 At End of Treatment 29.5 (∓20.7) 35.1 (∓16.8) t(25) = −0.76, p = n.s
PCL-5 Follow-up 32.7 (∓14.95) 28.1 (∓18.1) t(21) = 0.66, p = n.s
BDI-II Before Treatment 24.4 (∓9.2) 24.6 (∓12.3) t(24) = −0.05, p = n.s.
BDI-II At End of Treatment 16.5 (∓12.9) 17.1 (∓10.7) t(25) = −0.12, p = n.s.
BDI-II Follow-up 20.9 (∓12.2) 14.5 (∓11.1) t(22) = 1.4, p = n.s.
Time from Criteria A Trauma (years) 12.11 (∓8.62) 13.88 (∓11.18) t(23) = −0.45, p = n.s

Lifetime Substance Use/Dependence

(yes/no)

7/7 6/7 Χ2(1) = 1, p = n.s
Current MDD Episode 13/13 8/11 Χ2(1) = 1.94, p = n.s
Trauma Type
 Combat 4 0
 Violence 3 2
 Sexual 3 4
 Other 3 5